AstraZeneca Aktie
WKN: 886715 / ISIN: US0463531089
23.10.2023 16:48:50
|
AstraZeneca : Phase III Trial Of Datopotamab Deruxtecan In Breast Cancer Shows Improvement In PFS
(RTTNews) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) said positive results from the pivotal TROPION-Breast01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival or PFS compared to investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer previously treated with endocrine-based therapy and at least one systemic therapy.
Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
The companies noted that datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was well tolerated in post-endocrine therapy setting.
For the dual primary endpoint of overall survival, interim results numerically favored datopotamab deruxtecan over chemotherapy, however, results did not reach statistical significance at the time of this data cut-off. The trial is ongoing to assess overall survival.
For More Such Health News, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
23.07.25 |
Gewinne in New York: Börsianer lassen NASDAQ 100 steigen (finanzen.at) | |
17.07.25 |
Aufschläge in New York: Gewinne im NASDAQ 100 (finanzen.at) | |
17.07.25 |
Aufschläge in New York: NASDAQ 100 zeigt sich am Mittag fester (finanzen.at) | |
16.07.25 |
AstraZeneca-Aktie im Minus: Anselamimab hat Studienziel nicht erreicht (Dow Jones) | |
14.07.25 |
Erste Schätzungen: AstraZeneca gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
04.07.25 |
AstraZeneca-Aktie höher: Summit Therapeutics und AstraZeneca sprechen über Ivonescimab-Deal (Dow Jones) | |
03.07.25 |
NASDAQ-Handel: NASDAQ 100 verbucht zum Handelsende Gewinne (finanzen.at) | |
03.07.25 |
Freundlicher Handel in New York: NASDAQ 100-Anleger greifen nachmittags zu (finanzen.at) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 61,50 | 3,36% |
|